Sutrovax Inc is a vaccine innovation company based in South San Francisco, CA, dedicated to eliminating bacterial infections worldwide. They focus on developing high-fidelity and broad-spectrum vaccines to protect individuals from diseases such as invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella.
With their lead candidate, VAX-24, they aim to overcome the limitations of conventional vaccine approaches by utilizing advanced chemistry and synthetic techniques to produce vaccines that can break down bacteria's complex defense mechanisms while maintaining immunogenicity. Their pipeline includes other vaccine candidates targeting various diseases, including VAX-31, a 31-valent pneumococcal conjugate vaccine, as well as vaccines for Group A Strep, periodontitis, and Shigella.
Generated from the website